Genetic Testing Initiative
Dr. Alan Shuldiner discusses a new gene-testing initiative for cardiology patients at the University of Maryland Medical Center. As part of a new personalized medicine initiative, the medical center is offering genetic testing to help doctors determine which medication a patient should take after a stenting procedure in order to prevent blood clots that could lead to serious - and potentially fatal - heart attacks and strokes. Up to one-fourth of the U.S. population carries at least one abnormal copy of the CYP2C19 gene, and research has shown that as a result, these individuals do not metabolize the standard anti-clotting medication clopidogrel effectively.
Dr. Shuldiner, director of the Program in Personalized and Genomic Medicine at the University of Maryland School of Medicine, is leading the new gene-testing initiative at the medical center. Only a small number of hospitals in the United States have programs to offer routine genetic testing as part of their clinical practice.
Official News Release
Maryland Heart Center
Pharmacogenomics Research Network - National Institute of General Medical Sciences
This page was last updated: September 8, 2014